Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-09-09
2008-09-09
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S365000, C514S396000, C514S397000, C514S388000
Reexamination Certificate
active
10043877
ABSTRACT:
The present invention is directed to the use of benzimidazole derivatives for the treatment of tumors and in combination with tumor suppressor gene therapy. In a particular embodiment, treatment of p53-positive tumors with benzimidazole derivatives induces p53 expression and increases its half-life, resulting in apoptotic death of the tumor cells. Similarly, in conjunction with p53 gene therapy, benzimidazole derivatives induce p53 expression and accumulation in tumor cells regardless of their p53 status. The combination treatment subsequently elicits apoptosis of the tumor cells.
REFERENCES:
patent: 5767138 (1998-06-01), Camden
patent: 5880144 (1999-03-01), Camden
patent: 5900429 (1999-05-01), Camden
patent: 5929099 (1999-07-01), Camden
patent: 6028116 (2000-02-01), Sperl et al.
patent: 6046206 (2000-04-01), Pamukcu et al.
patent: 6077862 (2000-06-01), Camden
patent: 6211177 (2001-04-01), Sperl et al.
patent: 6262059 (2001-07-01), Pamukcu et al.
patent: 6262093 (2001-07-01), Camden
patent: 6348032 (2002-02-01), Sperl et al.
patent: 6369092 (2002-04-01), Pamukcu et al.
patent: 6380232 (2002-04-01), Quada, Jr. et al.
patent: 6407131 (2002-06-01), Quada, Jr. et al.
patent: 6420411 (2002-07-01), Camden et al.
patent: 2 342 470 (2002-09-01), None
patent: WO 98/32440 (1998-07-01), None
patent: WO 98/51304 (1998-11-01), None
patent: WO00/41669 (2000-07-01), None
patent: WO 00/41669 (2000-07-01), None
patent: WO 02/076454 (2002-10-01), None
Perdoma et al., J. Cancer Res. Clin. Oncol. 1998, 124, 10-18.
Perdoma et al. (J. Cancer Res. Clin. Oncol. 1998, 124, 10-18).
Delatour et al. (Therapie 1976; 31 (4); 505-515).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Delatour et al. (IDS, Therapie 1976; 31 (4); 505-515).
Nasr et al. (Journal of Pharmaceutical Sciences 1985; 74: 831-836).
Lucci et al. (Cancer; 86:300-311, published online on Nov. 2000).
Su et al. (PNAS 1998; 95: 14400-14405).
Perdoma et al. ( J. Cancer Res. Clin. Oncol. 1998, 124, 10-18).
Albonico et al., “Control strategies for human intestinal nematode infections,”Adv. Parasitol., 42:277-341, 1999.
Braithwaite et al., “Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease,”Eur. J. Clin Pharmacol., 22:161-169, 1982.
Braithwaite et al., “Cyst and host tissue concentrations of mebendazole in patients undergoing surgery for hydatid disease,”The Medical J. of Australia, 2:383-384, 1983.
Bryceson et al., “Bioavailability and tolerability of mebendazole in patients with inoperable hydatid disease,”Trans. of the Royal Soc. Of Tropical Med. And Hygiene, 76:563-564, 1982.
Burgat-Sacaze et al., “Bound residues of veterinary drugs: bioavailability and toxicological implications,”Ann. Rech. Vet., 13:277-289, 1981.
Chiba et al., “Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol,”Chem. Pharm Bull., 39(8):2158-2160, 1991.
Dawson and Watson, “The effect of dose form on the bioavailability of mebendazole in man,”Br. J. Clin Pharmac., 19:87-90, 1985.
Dawson et al., “The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole,”Br. J. Clin Pharmac., 14:453-455, 1982.
Delatour and Richard, “Embryogenic and antimitotic properties of benzimidazole series,”Therapie, 31:505-515, 1976, with English translation.
Delatour et al., “Embryotoxic and antimitotic properties of parbendazole, mebendazole and cambendazole,”C R Acad Sci Hebd Seances Acad Sci D, 282(5):517-518, 1976, with English translation.
Description of Vermox® (mebendazole), pp. 1442 FromPhysicians' Desk Reference, Janssen Pharmaceutica, c1998.
Edwards and Breckenridge, “Clinical pharmacokinetics of anthelmintic drugs,”Clin. Pharmacokinet., 15:67-93, 1988.
Elhajouji et al., “Indication for thresholds of chromosome non-disjunction versus chromosome lagging induced by spindle inhibitors in vitro in human lymphocytes,”Mutagenesis, 12:133-140, 1997.
Farghali and Masek, “Immunopharmacologic agents in the amelioration of hepatic injuries,”International J. of Immunopharmacology, 20:125-139, 1998.
Galtier et al., “Fasciola hepatica: mebendazole and thiabendazole pharmacokinetics in sheep,”Exp. Parasitology, 79:166-176, 1994.
Kromer, “Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds,”Digestion, 56:443-454, 1995.
Lubega and Prichard, “Interaction of benzimidazole anthelmintics withHaemonchus contortustubulin: binding affinity and anthelmintic efficacy,”Exp. Parasitol., 73:203-213, 1991.
Lubega and Prichard, “Specific interaction of benzimidazole anthelmintics with tubulin from developing stages of thiabendazole-susceptible and resistantHaemonchus contortus,” Biochem. Pharacol., 41:93-101, 1991.
Michiels et al., “The pharmacokinetics of mebendazole and flubendazole in animals and man,”Arch. Int. Pharmacodyn., 256:180-191, 1982.
Upton, “Pharmacokinetic interactions between theophylline and other medication (Part I),”Clin. Pharmacokinet., 20:66-80, 1991.
Van Hummelen et al., “Clastogenic and aneugenic effects of three benzimidazole derivatives in the in vitro micronucleus test using human lymphocytes,”Mutagenesis, 10:23-29, 1995.
Bossche et al.,Chemotherapy of Gastrointestinal Helminths., Arundel et al., (eds.), Springer-Verlag, 1985, In: Handbook of Experimental Pharmacology, vol. 77, Born et al., (eds.).
Davidse, “Benzimidazole fungicides: mechanism of action and biological impact,”Ann. Rev. Phytopathol., 24:43-65, 1986.
Friedman and Platzer, “Interaction of anthelmintic benzimidazoles and benzimidazole derivatives with bovine brain tubulin,”Biochim. Biophys. Acta, 544:605-614, 1978.
Friedman and Platzer, “Interaction of anthelmintic benzimidazoles with ascaris suum embronic tubulin,”Biochim. Biophys. Acta, 630:271-278, 1980.
Gottschall et al., “The metabolism of benzimidazole anthelmintics,”Parasitol. Today, 6:115-124, 1990.
Kohler and Bachmann, “Intestinal tubulin as possible target for the chemotherapeutic action of mebendazole in parasitic nematodes,”Mol. Biochem. Parasitol., 4:325-336, 1981.
Lacey and Prichard, “Interactions of benzimidazoles (BZ) with tubulin from BZ-sensitive and BZ-resistant isolates ofHaemonchus contortus,” Mol Biochem Parasitol, 19:171-181, 1986.
Lacey and Watson, “Structure-activity relationships of benzimidazole carbamates as inhibitors of mammalian tubulin, in vitro,”Biochem. Pharmacol., 34(7):1073-1077, 1985.
Lacey and Watson, “Activity of benzimidazole carbamates against L1210 mouse leukaemia cells: correlation with in vitro tubulin polymerization assay,”Biochem. Pharmacol., 34(19):3603-3605, 1985.
Lacey, “The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles,”Int. J. Parasitol., 18:885-936, 1988.
Lanusse et al., “Methimazole-mediated modulation of netobimin biotransformation in sheep: a pharmacokinetic assessment,”J Vet Pharmacol Ther, 15(3):267-274, 1992.
Lanusse et al., “Comparative sulphoxidation of albendazole by sheep and cattle liver microsomes and the inhibitory effect of methimazole,”Xenobiotica, 23(3):285-295, 1993.
Lubega, and Prichard, “Specific interaction of benzimidazole anthelmintics with tubulin: high-affinity binding and benzimidazole resistance inHaemonchus contortus,” Mol. Biochem. Parasitol., 38:221-232, 1990.
Nare et al., “Benzimidazoles, potent anti-mitotic drugs: substrates for the P-glycoprotein transporter in multidrug-resistant cells,”Biochem. Pharmacol.
Chada Sunil
Mhashilkar Abner
Mukhopadhyay Tapas
Roth Jack A.
Board of Regents , The University of Texas System
Fetterolf Brandon J
Fulbright & Jaworski L.L.P.
Introgen Therapeutics Inc.
LandOfFree
Antihelminthic drugs as a treatment for hyperproliferative... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antihelminthic drugs as a treatment for hyperproliferative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antihelminthic drugs as a treatment for hyperproliferative... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3951352